{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:14:18Z","timestamp":1791609258650,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"vor","delay-in-days":236,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/j.zefq.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T20:31:09Z","timestamp":1442349069000},"page":"417-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Besonderheiten von Onkologischen Studien im Rahmen der fr\u00fchen Nutzenbewertung von Arzneimitteln"],"prefix":"10.1016","volume":"109","author":[{"given":"Stefan","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.zefq.2015.08.003_bib0250","unstructured":"Neue Arzneimittel. Umstrittener Mehrwert. Der Tagesspiegel [online] 25.08.2012. URL: http:\/\/www.tagesspiegel.de\/wirtschaft\/neue-arzneimittel-umstrittener-mehrwert\/7053572.html."},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0255","first-page":"285","article-title":"Athletic records and human endurance","volume":"69","author":"Riegel","year":"1981","journal-title":"Am Sci"},{"issue":"5","key":"10.1016\/j.zefq.2015.08.003_bib0260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-010-0808-3","article-title":"Superior efficacy of new medicines?","volume":"66","author":"van Luijn","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.zefq.2015.08.003_bib0265","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00228-013-1577-6","article-title":"Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France","volume":"69","author":"Van Wilder","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.zefq.2015.08.003_bib0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2052-3211-6-8","article-title":"Assessment of the therapeutic value of new medicines marketed in Australia","volume":"6","author":"Vitry","year":"2013","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.zefq.2015.08.003_bib0275","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie. Fr\u00fche Nutzenbewertung neuer Arzneimittel in Deutschland 2011\u20132014. 6. Band der Gesundheitspolitischen Schriftenreihe der DGHO [online]. 01.04.2015 [Zugriff: 14.06.2015]. URL: http:\/\/www.dgho.de\/informationen\/gesundheitspolitische-schriftenreihe\/band-6."},{"key":"10.1016\/j.zefq.2015.08.003_bib0280","doi-asserted-by":"crossref","unstructured":"Verordnung \u00fcber die Nutzenbewertung von Arzneimitteln nach \u00a7 35a Absatz 1 SGB V f\u00fcr Erstattungsvereinbarungen nach \u00a7 130b SGB V (Arzneimittel-Nutzenbewertungsverordnung - AM-NutzenV). Bundesgesetzblatt 2010; Teil I(68): 2324\u20132328.","DOI":"10.7328\/BGBL_2010_0000553_H68"},{"key":"10.1016\/j.zefq.2015.08.003_bib0285","unstructured":"Gemeinsamer Bundesausschuss. Verfahrensordnung des Gemeinsamen Bundesausschusses [online]. 18.12.2014 [Zugriff: 14.06.2015]. URL: https:\/\/www.g-ba.de\/downloads\/62-492-1002\/VerfO_2014-12-18_iK-2015-04-16.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0290","unstructured":"Drittes Gesetz zur \u00c4nderung arzneimittelrechtlicher und anderer Vorschriften. Bundesgesetzblatt 2013; Teil I(47): 3108\u20133112."},{"key":"10.1016\/j.zefq.2015.08.003_bib0295","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden: Version 4.2 [online]. 22.04.2015 [Zugriff: 14.06.2015]. URL: https:\/\/www.iqwig.de\/download\/IQWiG_Methoden_Version_4-2.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0300","article-title":"Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs","author":"Skipka","year":"2015","journal-title":"Biom J"},{"issue":"7589","key":"10.1016\/j.zefq.2015.08.003_bib0305","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/bmj.39070.527986.68","article-title":"When are randomised trials unnecessary? Picking signal from noise","volume":"334","author":"Glasziou","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.zefq.2015.08.003_bib0310","unstructured":"European Medicines Agency. Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies - draft [online]. 17.06.2014 [Zugriff: 14.06.2015]. URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500168852.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0315","unstructured":"Bender R. Probleme bei der Analyse unerw\u00fcnschter Ereignisse im Rahmen der Nutzenbewertung von Arzneimitteln [online]. In: GMDS 2014: 59. Jahrestagung der Deutschen Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie; Workshop \u201dMethodische Aspekte bei der Nutzenbewertung von Arzneimitteln\"; 07.-10.09.2014; G\u00f6ttingen, Deutschland. 10.09.2014 [Zugriff: 14.06.2015]. URL: http:\/\/www.gmds.de\/tagungen\/2014\/downloads\/Workshops\/ID14_Workshop_Nutzenbewertung_Hauschke.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0320","unstructured":"Bender RL, S. Analyse unerw\u00fcnschter Ereignisse im Rahmen der Nutzenbewertung von Arzneimitteln [online]. In: Biometrisches Kolloquium des Instituts f\u00fcr Medizinische Biometrie und Medizinische Informatik (IMBI) Freiburg; 28.04.2014; Freiburg, Deutschland. 28.04.2014 [Zugriff: 14.06.2015]. URL: http:\/\/portal.uni-freiburg.de\/imbi\/dateien\/biometrie\/pdfs\/kolloq\/archiv\/2011-2015\/bender."},{"key":"10.1016\/j.zefq.2015.08.003_bib0325","unstructured":"European Medicines Agency. Concept paper on the need to revise the \u2018Guideline on the evaluation of anticancer medicinal products in man\u2018 in order to provide guidance on the reporting of safety data from clinical trials [online]. 31.03.2015 [Zugriff: 14.06.2015]. URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/04\/WC500186307.pdf."},{"issue":"12","key":"10.1016\/j.zefq.2015.08.003_bib0330","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis","volume":"303","author":"Bassler","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jclinepi.2007.07.016","article-title":"Early stopping of randomized clinical trials for overt efficacy is problematic","volume":"61","author":"Bassler","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.zefq.2015.08.003_bib0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0962280211432211","article-title":"Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?","volume":"22","author":"Bassler","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0345","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/1740774511407358","article-title":"The 6-MP versus placebo clinical trial in acute leukemia","volume":"8","author":"Gehan","year":"2011","journal-title":"Clin Trials"},{"issue":"2","key":"10.1016\/j.zefq.2015.08.003_bib0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.zefq.2013.03.004","article-title":"Bei Krebs liegen die Dinge anders und es gelten faktisch andere Ma\u00dfst\u00e4be [Editorial]","volume":"107","author":"Windeler","year":"2013","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"2","key":"10.1016\/j.zefq.2015.08.003_bib0355","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.zefq.2013.02.001","article-title":"Vom Ende her gedacht - ist die Frage \u201eKrebs\u201c f\u00fcr Betroffene und Betreuer bedeutsam?","volume":"107","author":"Bausewein","year":"2013","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"9","key":"10.1016\/j.zefq.2015.08.003_bib0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.zefq.2011.01.006","article-title":"Klinische Studien in der Onkologie \u2013 Defizite und L\u00f6sungsvorschl\u00e4ge","volume":"105","author":"Schott","year":"2011","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.zefq.2015.08.003_bib0365","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000348253","article-title":"Neue Arzneimittel in der Onkologie: Merkmale klinischer Zulassungsstudien und Argumente f\u00fcr die rasche Durchf\u00fchrung unabh\u00e4ngiger klinischer Studien nach der Zulassung","volume":"36 Suppl 2","author":"Ludwig","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.zefq.2015.08.003_bib0370","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Kuration vs. Palliation: Versuch einer Begriffskl\u00e4rung; Auftrag GA12-01; Version 1.1 [online]. 04.04.2014 [Zugriff: 14.06.2015]. URL: https:\/\/www.iqwig.de\/download\/GA12-01_Arbeitspapier_Kuration-versus-Palliation.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0375","doi-asserted-by":"crossref","first-page":"d8141","DOI":"10.1136\/bmj.d8141","article-title":"Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications","volume":"344","author":"Wieseler","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.zefq.2015.08.003_bib0380","doi-asserted-by":"crossref","first-page":"e1001526","DOI":"10.1371\/journal.pmed.1001526","article-title":"Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data","volume":"10","author":"Wieseler","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.zefq.2015.08.003_bib0385","doi-asserted-by":"crossref","first-page":"h796","DOI":"10.1136\/bmj.h796","article-title":"Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports","volume":"350","author":"K\u00f6hler","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.zefq.2015.08.003_bib0390","unstructured":"Food and Drug Administration. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products [online]. 01.05.1998 [Zugriff: 14.06.2015]. URL: http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm078749.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0395","unstructured":"European Medicines Agency. Points to consider on application with 1. Meta-analyses; 2. One pivotal study [online]. 31.05.2001 [Zugriff: 14.06.2015]. URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003657.pdf."},{"key":"10.1016\/j.zefq.2015.08.003_bib0400","doi-asserted-by":"crossref","unstructured":"Gartlehner G, Dobrescu A, Evans TS, Thaler K, Nussbaumer B, Sommer I, et al. Average effect estimates remain similar as evidence evolves from single trials to high-quality bodies of evidence: a meta-epidemiologic study. J Clin Epidemiol 05.04.2015 [Epub ahead of print].","DOI":"10.1016\/j.jclinepi.2015.02.013"},{"issue":"2","key":"10.1016\/j.zefq.2015.08.003_bib0405","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cct.2013.12.003","article-title":"The misguided ethics of crossover trials","volume":"37","author":"Prasad","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0410","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cpt.59","article-title":"From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients","volume":"97","author":"Eichler","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0415","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2011.345","article-title":"Adaptive licensing: taking the next step in the evolution of drug approval","volume":"91","author":"Eichler","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.zefq.2015.08.003_bib0420","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMhle1311493","article-title":"New FDA breakthrough-drug category--implications for patients","volume":"370","author":"Darrow","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.zefq.2015.08.003_bib0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.1","article-title":"FDA designations for therapeutics and their impact on drug development and regulatory review outcomes","volume":"97","author":"Kesselheim","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.zefq.2015.08.003_bib0430","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/djr062","article-title":"Accelerated approval of oncology products: the food and drug administration experience","volume":"103","author":"Johnson","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.zefq.2015.08.003_bib0435","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1467-9566.2010.01310.x","article-title":"Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation","volume":"33","author":"Davis","year":"2011","journal-title":"Sociol Health Illn"},{"issue":"2","key":"10.1016\/j.zefq.2015.08.003_bib0440","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jama.2013.7900","article-title":"The Food and Drug Administration Amendments Act and postmarketing commitments","volume":"310","author":"Fain","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.zefq.2015.08.003_bib0445","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamainternmed.2013.11813","article-title":"Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.zefq.2015.08.003_bib0450","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2288-11-4","article-title":"Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study","volume":"11","author":"Morden","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.zefq.2015.08.003_bib0455","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Making"},{"issue":"19","key":"10.1016\/j.zefq.2015.08.003_bib0460","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.zefq.2015.08.003_bib0465","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.zefq.2015.08.003_bib0470","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005\u20132012","volume":"311","author":"Downing","year":"2014","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.zefq.2015.08.003_bib0475","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.zefq.2015.08.003_bib0480","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jval.2014.05.001","article-title":"Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach","volume":"17","author":"Ruof","year":"2014","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.zefq.2015.08.003_bib0485","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.zefq.2015.08.003_bib0245","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921715001762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921715001762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T16:08:46Z","timestamp":1567181326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1865921715001762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"alternative-id":["S1865921715001762"],"URL":"https:\/\/doi.org\/10.1016\/j.zefq.2015.08.003","relation":{},"ISSN":["1865-9217"],"issn-type":[{"value":"1865-9217","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Besonderheiten von Onkologischen Studien im Rahmen der fr\u00fchen Nutzenbewertung von Arzneimitteln","name":"articletitle","label":"Article Title"},{"value":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.zefq.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier GmbH","name":"copyright","label":"Copyright"}]}}